UCB, Inc. is a biopharmaceutical company that develops treatments for serious immune and nervous system diseases. It lobbies Congress on health policy matters affecting drug access and innovation, and on tax rules such as international tax, corporate tax rates, and research and development tax incentives. It reports using Venn Strategies for lobbying work.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
MICHAEL SPIRA
The latest disclosures for this client.
VENN STRATEGIES
Q1VENN STRATEGIES
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
VENN STRATEGIES
mr JUSTIN ROBERT LIVESEY
VENN STRATEGIES
SAMUEL GOODSTEIN
VENN STRATEGIES
MELISSA FRANCIS (FORMERLY BONICELLI)
VENN STRATEGIES
mr JONATHAN PYATT
VENN STRATEGIES
VENN STRATEGIES
Q3VENN STRATEGIES
Q2VENN STRATEGIES
Q1